EPISODE · Mar 17, 2022 · 14 MIN
In conversation with... John Collinge
from Listen to The Lancet Neurology · host The Lancet
John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.
Embed this episode
NOW PLAYING
In conversation with... John Collinge
0:00
14:45
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Listen to The Lancet Neurology?
This episode is 14 minutes long.
When was this Listen to The Lancet Neurology episode published?
This episode was published on March 17, 2022.
Can I download this Listen to The Lancet Neurology episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!